| Today’s Big NewsNov 22, 2024 |
| By Nick Paul Taylor A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate. The biotech previously reported that the patient was in critical condition. |
|
|
|
By James Waldron AstraZeneca has ended work on an opioid use disorder drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. |
By Darren Incorvaia Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and CEO Helen Torley said in a Nov. 22 release. |
Sponsored by Adaptive Biotechnologies Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance. |
|
Explore the latest additions to the GS®️ expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During this webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems. 
|
|
By Gabrielle Masson After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for chapter 11 bankruptcy. |
Sponsored by Dell Technologies Head of Life Sciences Strategy Alex Long shares key insights and advice for IT professionals working to enable healthcare’s technology transformation. |
By Darren Incorvaia After two and a half years at sea, Flagship Pioneering-backed cell signaling company Sonata Therapeutics is whittling down its crew by 20 employees, a company spokesperson confirmed to Fierce Biotech. |
By James Waldron Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and whether the company will become an autoimmune disease player. |
By Fraiser Kansteiner While one might expect a positive readout from a biotech’s lead candidate to boost the company’s stock price, Pyxis Oncology’s shares—which have tumbled more than 40% this week—tell a different story. |
By Darren Incorvaia,Zoey Becker Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino effect of leadership changes. |
By Fraiser Kansteiner Given president-elect Donald Trump’s focus on matters beyond healthcare and a more hands-off approach to government regulation, the life sciences realm is unlikely to face a major shakeup—at least for now—Baird’s biotech specialist Mike Perrone opined Thursday. |
By Ayla Ellison,Andrea Park,Gabrielle Masson This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
By Eric Sagonowsky Merck and Johnson & Johnson are cutting staffers in China as they face local headwinds, according to reports. Australia’s CSL is winding down operations at a cell and gene therapy R&D site in California. Kyowa Kirin inked a commercialization and development deal with Kuro Oncology. Plus more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
The future of gene therapy is here, but with it comes manufacturing constraints, supply chain issues, and regulatory questions. Join us on November 20 for the Fierce Cell and Gene Virtual Event. Register Now! 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
